Tirzide 2.5 mg (Tirzepatide INN)

Dual GIP & GLP-1 Receptor Agonist for Type 2 Diabetes Management

💊 Pharmacology:

Tirzepatide is a first-in-class dual incretin receptor agonist that activates:

• Glucose-dependent insulinotropic polypeptide (GIP) receptors

• Glucagon-like peptide-1 (GLP-1) receptors

This dual mechanism:

• Enhances glucose-dependent insulin secretion

• Reduces glucagon levels

• Delays gastric emptying

• Promotes satiety and weight loss

• Improves overall glycemic control

It provides superior HbA1c reduction compared to traditional GLP-1 therapies in many patients.

📌 Indications:

Tirzide® 2.5 mg is indicated for:

• Type 2 Diabetes Mellitus as an adjunct to diet and exercise

• Patients requiring improved glycemic control

• May also support weight management in diabetic patients

Not indicated for Type 1 Diabetes or diabetic ketoacidosis.

💉 Dosage & Administration:

• Starting dose: 2.5 mg once weekly (subcutaneous injection)

• Dose escalation may occur based on physician recommendation

• Administer on the same day each week

• Can be taken with or without meals

• Injection sites: abdomen, thigh, or upper arm

Follow medical guidance strictly for titration.

⚠️ Precautions & Warnings:

• Monitor blood glucose regularly

• Risk of gastrointestinal side effects (nausea, vomiting)

• Caution in patients with history of pancreatitis

• Monitor for hypoglycemia if used with insulin or sulfonylureas

• Not recommended in patients with severe gastrointestinal disease

❌ Contraindications:

• Hypersensitivity to Tirzepatide

• Personal or family history of medullary thyroid carcinoma (MTC)

• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

🤰 Pregnancy & Lactation:

• Not recommended during pregnancy

• Breastfeeding should be avoided during treatment

• Effective contraception advised during therapy

⚕️ Side Effects:

Common side effects include:

• Nausea

• Vomiting

• Diarrhea

• Decreased appetite

• Abdominal discomfort

• Injection site reactions

Serious but rare:

• Pancreatitis

• Severe hypoglycemia (when combined with insulin)

• Thyroid C-cell tumors (observed in animal studies)

🧊 Storage Conditions:

• Store refrigerated at 2°C–8°C

• Do not freeze

• Protect from light

• Keep out of reach of children